BATM to invest $450,000 in Opticul Diagnostics

pharmaceuticals
pharmaceuticals

BATM CEO: Opticul has invented a technology that is able to identify a type of bacteria in minutes instead of days.

BATM Advanced Communications Ltd. (LSE: BVC; TASE: BATM) has agreed to invest up to $450,000 in in vitro diagnostics device company, Opticul Diagnostics. BATM provides real-time technologies for the networked telecoms and medical laboratory equipment markets.

Opticul has developed a process for rapid diagnosis, using photonic laser technologies, of micro-organisms based on their outer morphology. The process - applied through the Optidet device - enables faster, lower cost and more reliable diagnostics compared with current technologies.

BATM and Opticul will conduct joint R&D in the U.S. and Israel to develop and launch the next prototype of Optidet. Of the agreed investment, $200,000 is being paid upfront in cash and the remainder as milestones are achieved. BATM will own 20% of the issued share capital of Opticul Diagnostics.

Opticul has already obtained US Food and Drug Administration (FDA) and European ISO approval for an early prototype.

BATM CEO Dr. Zvi Marom said, "Opticul has invented a truly disruptive technology that is able to identify a type of bacteria in minutes instead of days. This investment is complementary to our diagnostics business and adds another technology offering to our portfolio."

Published by Globes [online], Israel business news - www.globes-online.com - on September 8, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

pharmaceuticals
pharmaceuticals
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018